Independent Conference Highlights of the 2022 ASH Annual Meeting*

Results from the phase III TRIANGLE study showed improved failure-free survival and acceptable safety with the addition of ibrutinib to standard CIT with or without ASCT in patients 65 years of age or younger with previously untreated MCL.

The combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved a high CR rate at the end of treatment with low incidence of peripheral neuropathy and no episodes of febrile neutropenia.

In patients with DLBCL, MRD status by PhaseED-Seq was strongly prognostic of PFS, particularly at end of induction therapy.

In a cohort of untreated patients with CLL enriched for high-risk disease, the combination of acalabrutinib, venetoclax, and obinutuzumab resulted in high response rates.

Epcoritamab + rituximab/lenalidomide resulted in high response rates in both first-line and R/R FL with no severe CRS events.

Addition of acalabrutinib to lenalidomide and rituximab as initial treatment of MCL was associated with high MRD-negative complete responses in this preliminary study.

With extended follow-up, short-course brentuximab vedotin + AVD remains highly active in early-stage, unfavorable-risk classical Hodgkin lymphoma.

First-line ibrutinib + venetoclax showed ongoing efficacy in patients with CLL/SLL through a median follow-up of 56 months, with 3-year disease-free survival rates of 93% and 85% in patients with confirmed undetectable MRD receiving continued ibrutinib vs placebo, respectively.

Tazemetostat combined with lenalidomide and rituximab for previously treated FL showed no unexpected safety signals and preliminary evidence of a high response rate.

Consolidation with high-dose chemotherapy and ASCT reduced risk of disease progression and death compared with conventional chemoimmunotherapy in primary CNS lymphoma.

Zanubrutinib demonstrated superior ORR and PFS compared with ibrutinib in patients with R/R CLL/SLL.